Viracta Therapeutics, Inc. (VIRX)
USD 0.02
(14.44%)
USD 0.02
(14.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 13.23 Million USD | 213.95% |
| 2022 | -11.61 Million USD | 88.15% |
| 2021 | -98.07 Million USD | -139.73% |
| 2020 | -40.91 Million USD | -241.52% |
| 2019 | -11.97 Million USD | -90.14% |
| 2018 | -6.3 Million USD | 68.14% |
| 2017 | -19.77 Million USD | -409.97% |
| 2016 | 6.37 Million USD | 133.48% |
| 2015 | -19.05 Million USD | -47.36% |
| 2014 | -12.92 Million USD | -542.47% |
| 2013 | 2.92 Million USD | -68.65% |
| 2012 | 9.32 Million USD | -73.33% |
| 2011 | 34.94 Million USD | 345.69% |
| 2010 | -14.22 Million USD | -233.98% |
| 2009 | -4.25 Million USD | 32.37% |
| 2008 | -6.29 Million USD | 33.15% |
| 2007 | -9.41 Million USD | -122.45% |
| 2006 | -4.23 Million USD | 72.38% |
| 2005 | -15.33 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 6.79 Million USD | -48.67% |
| 2024 Q2 | 4.83 Million USD | -28.8% |
| 2023 Q3 | 12.7 Million USD | 12.83% |
| 2023 Q2 | 11.25 Million USD | 51.31% |
| 2023 Q1 | 7.44 Million USD | 164.05% |
| 2023 FY | 13.23 Million USD | 213.95% |
| 2023 Q4 | 13.23 Million USD | 4.21% |
| 2022 Q2 | -76.24 Million USD | 12.15% |
| 2022 Q1 | -86.79 Million USD | 11.51% |
| 2022 Q3 | -18.22 Million USD | 76.1% |
| 2022 FY | -11.61 Million USD | 88.15% |
| 2022 Q4 | -11.61 Million USD | 36.25% |
| 2021 FY | -98.07 Million USD | -139.73% |
| 2021 Q4 | -98.07 Million USD | 6.78% |
| 2021 Q3 | -105.2 Million USD | 10.0% |
| 2021 Q2 | -116.9 Million USD | 4.9% |
| 2021 Q1 | -122.92 Million USD | -200.47% |
| 2020 FY | -40.91 Million USD | -241.52% |
| 2020 Q1 | -13.82 Million USD | -113.37% |
| 2020 Q2 | -11.63 Million USD | 15.83% |
| 2020 Q4 | -40.91 Million USD | -59.57% |
| 2020 Q3 | -25.63 Million USD | -120.36% |
| 2019 Q2 | -3.25 Million USD | 81.48% |
| 2019 Q3 | -13.31 Million USD | -309.69% |
| 2019 FY | -11.97 Million USD | -90.14% |
| 2019 Q1 | -17.55 Million USD | -178.62% |
| 2019 Q4 | -6.47 Million USD | 51.36% |
| 2018 Q4 | -6.3 Million USD | 50.84% |
| 2018 FY | -6.3 Million USD | 68.14% |
| 2018 Q3 | -12.81 Million USD | -31.72% |
| 2018 Q2 | -9.72 Million USD | 31.07% |
| 2018 Q1 | -14.11 Million USD | 28.62% |
| 2017 Q3 | -795 Thousand USD | 82.65% |
| 2017 FY | -19.77 Million USD | -409.97% |
| 2017 Q4 | -19.77 Million USD | -2387.17% |
| 2017 Q2 | -4.58 Million USD | -250.54% |
| 2017 Q1 | 3.04 Million USD | -52.3% |
| 2016 FY | 6.37 Million USD | 133.48% |
| 2016 Q4 | 6.37 Million USD | -25.23% |
| 2016 Q1 | 3.98 Million USD | 120.92% |
| 2016 Q3 | 8.53 Million USD | 76.63% |
| 2016 Q2 | 4.83 Million USD | 21.2% |
| 2015 Q2 | -12.62 Million USD | -12.85% |
| 2015 Q4 | -19.05 Million USD | -110.59% |
| 2015 Q3 | -9.04 Million USD | 28.36% |
| 2015 FY | -19.05 Million USD | -47.36% |
| 2015 Q1 | -11.19 Million USD | 13.45% |
| 2014 Q2 | -12.95 Million USD | 62.33% |
| 2014 Q1 | -34.39 Million USD | -1276.93% |
| 2014 FY | -12.92 Million USD | -542.47% |
| 2014 Q3 | -9.23 Million USD | 28.71% |
| 2014 Q4 | -12.92 Million USD | -40.0% |
| 2013 Q2 | 15.37 Million USD | 36.23% |
| 2013 FY | 2.92 Million USD | -68.65% |
| 2013 Q4 | 2.92 Million USD | 273.62% |
| 2013 Q3 | -1.68 Million USD | -110.95% |
| 2013 Q1 | 11.28 Million USD | 21.08% |
| 2012 Q2 | -2.1 Million USD | -149.39% |
| 2012 Q3 | -17.64 Million USD | -737.7% |
| 2012 FY | 9.32 Million USD | -73.33% |
| 2012 Q4 | 9.32 Million USD | 152.83% |
| 2012 Q1 | 4.26 Million USD | -87.8% |
| 2011 FY | 34.94 Million USD | 345.69% |
| 2011 Q4 | 34.94 Million USD | 393.81% |
| 2011 Q3 | -11.89 Million USD | -57.04% |
| 2011 Q2 | -7.57 Million USD | 23.6% |
| 2011 Q1 | -9.91 Million USD | 30.3% |
| 2010 Q2 | -49.29 Million USD | -236.06% |
| 2010 Q3 | -14.14 Million USD | 71.32% |
| 2010 Q4 | -14.22 Million USD | -0.59% |
| 2010 Q1 | -14.66 Million USD | -244.45% |
| 2010 FY | -14.22 Million USD | -233.98% |
| 2009 Q2 | -6.84 Million USD | -59.86% |
| 2009 Q1 | -4.28 Million USD | 32.02% |
| 2009 Q4 | -4.25 Million USD | -9.98% |
| 2009 Q3 | -3.87 Million USD | 43.41% |
| 2009 FY | -4.25 Million USD | 32.37% |
| 2008 Q2 | -7.67 Million USD | -83.46% |
| 2008 Q1 | -4.18 Million USD | 55.56% |
| 2008 FY | -6.29 Million USD | 33.15% |
| 2008 Q4 | -6.29 Million USD | 9.04% |
| 2008 Q3 | -6.92 Million USD | 9.84% |
| 2007 FY | -9.41 Million USD | -122.45% |
| 2007 Q3 | -10.14 Million USD | -7.27% |
| 2007 Q1 | -9.16 Million USD | -116.48% |
| 2007 Q2 | -9.46 Million USD | -3.2% |
| 2007 Q4 | -9.41 Million USD | 7.18% |
| 2006 FY | -4.23 Million USD | 72.38% |
| 2006 Q4 | -4.23 Million USD | 83.67% |
| 2006 Q1 | -54.27 Million USD | -254.03% |
| 2006 Q2 | -60.3 Million USD | -11.11% |
| 2006 Q3 | -25.93 Million USD | 57.0% |
| 2005 Q4 | -15.33 Million USD | 99.97% |
| 2005 Q3 | -45.21 Billion USD | 0.0% |
| 2005 FY | -15.33 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -628.971% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 447.025% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -955.742% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 58.904% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 1509.904% |
| Better Therapeutics, Inc. | -860 Thousand USD | 1639.419% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 155.661% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -3930.861% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -189.694% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 327.357% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -313.977% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | -318.072% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -164.674% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 90.123% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -7289.897% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -7.298% |
| Molecular Templates, Inc. | 707 Thousand USD | -1772.56% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -2919.542% |
| NexImmune, Inc. | -3.13 Million USD | 522.48% |
| Orgenesis Inc. | 21.78 Million USD | 39.226% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -406.078% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 2658533.735% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 381.044% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 10727.333% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 88.059% |
| Statera Biopharma, Inc. | 14.41 Million USD | 8.167% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 274.289% |
| Trevena, Inc. | 2.25 Million USD | -486.315% |
| Vaxxinity, Inc. | 10.13 Million USD | -30.665% |
| Vaccinex, Inc. | -1.28 Million USD | 1127.873% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -3743.563% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -18297.21% |